Entera Bio (ENTX) Retained Earnings (2017 - 2026)

Entera Bio (ENTX) has reported Retained Earnings for 10 consecutive years, with -$128.9 million the latest figure, recorded in Q1 2026.

• Quarterly Retained Earnings fell 10.64% year-over-year to -$128.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$128.9 million (down 10.64% YoY) and the FY2025 annual result came in at -$125.4 million, down 10.04% from the prior year.
• Retained Earnings slipped to -$128.9 million in Q1 2026 per ENTX's latest filing, from -$125.4 million in the prior quarter.
• Over the last five years, Retained Earnings for ENTX reached as high as -$86.2 million in Q1 2022 and fell as low as -$128.9 million in Q1 2026.
• A 5-year average of -$107.1 million and a median of -$106.4 million in 2024 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2022 — Retained Earnings plunged 186.72% — and 2024, when it retreated 8.53%.
• Year by year, Retained Earnings stood at -$95.5 million in 2022, then retreated by 9.31% to -$104.4 million in 2023, then fell by 9.14% to -$113.9 million in 2024, then decreased by 10.04% to -$125.4 million in 2025, then slipped by 2.82% to -$128.9 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$128.9 million, -$125.4 million, and -$122.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.